Edwards Lifesciences (EW) Amortization of Deferred Charges (2019 - 2021)
Edwards Lifesciences has reported Amortization of Deferred Charges over the past 3 years, most recently at $7.1 million for Q4 2021.
- Quarterly results put Amortization of Deferred Charges at $7.1 million for Q4 2021, down 5.33% from a year ago — trailing twelve months through Dec 2021 was $28.5 million (up 1.06% YoY), and the annual figure for FY2021 was $28.5 million, up 1.06%.
- Amortization of Deferred Charges for Q4 2021 was $7.1 million at Edwards Lifesciences, roughly flat from $7.1 million in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for EW hit a ceiling of $7.5 million in Q4 2020 and a floor of $5.7 million in Q1 2019.
- Median Amortization of Deferred Charges over the past 3 years was $7.0 million (2019), compared with a mean of $6.8 million.
- Biggest five-year swings in Amortization of Deferred Charges: increased 17.54% in 2020 and later dropped 5.33% in 2021.
- Edwards Lifesciences' Amortization of Deferred Charges stood at $6.6 million in 2019, then grew by 13.64% to $7.5 million in 2020, then dropped by 5.33% to $7.1 million in 2021.
- The last three reported values for Amortization of Deferred Charges were $7.1 million (Q4 2021), $7.1 million (Q3 2021), and $7.0 million (Q2 2021) per Business Quant data.